pSivida’s Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis

pSivida (NASDAQ:PSDV) a leader in the development of sustained release drug products and technologies, today announced that results from the Company’s second Phase 3 trial for Durasert three-year treatment for posterior segment uveitis confirmed a significant reduction in uveitis recurrence rate at 12 months.

As quoted in the press release:

Patients requiring IOP-lowering therapy at any time during the first 12 months of follow-up were 50.5% for Durasert and 51.9% for sham. Only one patient, assigned to Durasert, required IOP surgery during the first 12 months of follow-up.

Click here to read the full press release.